Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.34 |
| ▸ | PDE8A | O60658 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960856 | 1.00 | SLC6A2 (0.39) | SLC6A2MAP3K14L3MBTL1POLBPDE8B | |
| SCHEMBL21960857 | 1.00 | SLC6A2 (0.39) | SLC6A2MAP3K14L3MBTL1POLBPDE8B | |
| SCHEMBL25745822 | 0.82 | MAP3K14 (0.37) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL23880130 | 0.81 | SLC6A2 (0.39) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL23880138 | 0.81 | SLC6A2 (0.39) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL23880136 | 0.81 | SLC6A2 (0.39) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL21960368 | 0.79 | PIK3CA (0.46) | L3MBTL1POLBPDE8BGAA | |
| SCHEMBL21964582 | 0.79 | SLC6A2 (0.38) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL21960385 | 0.79 | SLC6A2 (0.38) | SLC6A2MAP3K14PDE8BHRH3ACKR3 | |
| SCHEMBL21961347 | 0.78 | L3MBTL1 (0.40) | MAP3K14L3MBTL1POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | SLC6A2 4797/4885MAP3K14 4/4885L3MBTL1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.